| |
[摘要]：Chronic hepatitis B is a serious disease both worldwide and in the United States. There ore two types of drugs available to treat chronic hepatitis B virus (HBV) infection: interferons that boost the immune system, and antiviral or nucleoside analogues that ore designed to interfere with HBVDNA to prevent its replication. This review focuses on nucleoside antivirals, namely lamivudine, entecavir and telbivudine, which ore widely prescribed for patients with the disease, particularly lamivudine. Additionally, current Food and Drug Administration-approved nucleoside antivirals for hepatitis B will be briefly highlighted. Comparisons ore performed based on previous clinical trials from primary sources. Treatments with entecavir and telbivudine ore compared with lamivudine treatment in regard to pharmacotherapy, resistance and cost-effectiveness. Outcomes varied depending on each trial, but the main findings were more favorable for entecavir and telbivudine treatments than for lamivudine treatment. It was concluded that entecavir treatment is associated with better outcomes than lamivudine in the three aspects studied. Similarly, telbivudine showed more improvements than lamivudine in oil three areas. Concomitant pharmacotherapy, especially in lamivudine-refractory patients, demonstrated significant improvement in the management of chronic hepatitis B. Furthermore, the availability of hepatitis B vaccines should enable us to prevent the occurrence of the disease. |
|
